Company: CERO
Filing Date: 2025-05-27
Form Type: POS AM
Source: 0001213900-25-047469
Chunk: 297

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-27
Form: POS AM
Chunk 297
---
, which may be changed. The sale of our Common Stock offered by this prospectus could be effected in one or more of the following methods:

| ● | ordinary brokers’ transactions; |

| ● | transactions involving cross or block trades; |

| ● | through brokers, dealers, or underwriters who may act solely as agents; |

| ● | “at the market” into an existing market for our Common 
 Stock;                                                 |

| ● | in other ways not involving market makers or established business markets, 
 including direct sales to purchasers or sales effected through agents;     |

| ● | in privately negotiated transactions; or |

| ● | any combination of the foregoing. |

In order to comply with the securities laws of certain states, if applicable, the shares may be sold only through registered or licensed brokers or dealers. In addition, in certain states, the shares may not be sold unless they have been registered or qualified for sale in the state or an exemption from the state’s registration or qualification requirement is available and complied with. The Selling Securityholder is an “underwriter” within the meaning of Section 2(a)(11) of the Securities Act. The Selling Securityholder has informed us that it intends to use one or more registered broker-dealers to effectuate all sales, if any, of our Common Stock that it has acquired and may in the future acquire from us pursuant to the Purchase Agreements. Such sales will be made at prices and at terms then prevailing or at prices related to the then current market price. Each such registered broker-dealer will be an underwriter within the meaning of Section 2(a)(11) of the Securities Act. The Selling Securityholder has informed us that each such broker-dealer will receive commissions from the Selling Securityholder that will not exceed customary brokerage commissions. Brokers, dealers, underwriters or agents participating in the distribution of our Common Stock offered by this prospectus may receive compensation in the form of commissions, discounts, or concessions from the purchasers, for whom the broker-dealers may act as agent, of the shares sold by the Selling Securityholder through this prospectus. The compensation paid to any such particular broker-dealer by any such purchasers of our Common Stock sold by the selling shareholder may be less than or in excess of customary commissions. Neither we nor the applicable Selling Securityholder can presently estimate the amount of compensation that any agent will receive from any purchasers of our Common Stock sold by the Selling Securityholder. We know of no existing arrangements between the Selling Securityholder or any other shareholder,